Centrexion Therapeutics

General Information
Business:

 

We are a late clinical-stage biopharmaceutical company focused on becoming the leader in identifying, developing and commercializing novel, non-opioid and non-addictive therapies to address the large unmet medical need for the treatment of chronic pain. Pain is a protective reaction that alerts the body to the presence of actual or potential tissue damage so that necessary corrective responses can be mounted. The National Institutes of Health, or NIH, defines chronic pain as pain that persists beyond the normal healing time of an injury or that persists longer than three months. As of 2011, over 40 million adults in the United States and over 1 billion people worldwide suffer from chronic pain each year.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 14
Founded: 2013
Contact Information
Address 200 State Street, Boston, MA 02109, US
Phone Number (617) 837-6911
Web Address http://www.centrexion.com
View Prospectus: Centrexion Therapeutics
Financial Information
Market Cap $332.4mil
Revenues $0 mil (last 12 months)
Net Income $-33.4 mil (last 12 months)
IPO Profile
Symbol CNTX
Exchange NASDAQ
Shares (millions): 5.0
Price range $14.00 - $16.00
Est. $ Volume $75.0 mil
Manager / Joint Managers BofA Merrill Lynch/ Leerink Partners/ Evercore ISI
CO-Managers -
Expected To Trade: 11/15/2018
Status: Postponed
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change